DNA methylation biomarkers to identify epigenetically abnormal spermatozoa in male partners from couples experiencing recurrent pregnancy loss

Epigenetics. 2023 Dec;18(1):2252244. doi: 10.1080/15592294.2023.2252244.

Abstract

Previously, we showed that DNA methylation defects in spermatozoa from male partners of couples undergoing recurrent pregnancy loss (RPL) could be a contributing paternal factor. In the present study, we aimed to determine whether the methylation levels of selected imprinted genes can be used as diagnostic markers to identify epigenetically abnormal spermatozoa sample in these cases. The methylation levels of selected imprinted genes in spermatozoa, which were previously found to be differentially methylated, were combined into a probability score (between 0-1) using multiple logistic regression. Different combinations of these genes were investigated using Receiver Operating Characteristic analysis, and the threshold values were experimentally validated in an independent cohort of 38 control and 45 RPL spermatozoa samples. Among the different combinations investigated, a combination of five imprinted genes comprising IGF2-H19 DMR, IG-DMR, ZAC, KvDMR, and PEG3 (AUC = 0.88) with a threshold value of 0.61 was selected with a specificity of 90.41% and sensitivity of 70%. The results from the validation study indicated that 97% of the control samples had probability scores below this threshold, whereas 40% of the RPL samples were above this threshold with a post-hoc power of 97.8%. Thus, this combination can correctly classify control samples and potentially identify epigenetically abnormal spermatozoa samples in the male partners of couples undergoing RPL. We propose that the combined DNA methylation levels of these imprinted genes can be used as a diagnostic tool to identify spermatozoa samples with epigenetic defects which could contribute to the pathophysiology of RPL and the couple could be counselled appropriately.

Keywords: DNA methylation; Spermatozoa; imprinted genes; recurrent pregnancy loss.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • DNA Methylation*
  • Epigenomics
  • Female
  • Humans
  • Male
  • Pregnancy
  • Protein Processing, Post-Translational
  • Teratozoospermia*

Substances

  • Biomarkers

Grants and funding

This research was funded by the Department of Science and Technology, Science and Engineering Research Board [EMR/2014/000145], and the ICMR-National Institute for Research in Reproductive and Child Health intramural funds [RA/1225/03-2022].